Related Experiment Videos
Pure class III agents for prevention of sudden cardiac death
1Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. cpratt@bcm.tmc.edu
Insights
Clinical trials of antiarrhythmic drugs in post-myocardial infarction patients have yielded disappointing results. While IKr blockers showed promise, none reduced mortality in these high-risk individuals, impacting their use in atrial fibrillation treatment.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Type I antiarrhythmic drugs have shown limited efficacy in post-myocardial infarction patients.
- There was an expectation that IKr blockers could decrease sudden cardiac death in the post-infarct population.
Purpose of the Study:
- To review the outcomes of clinical trials investigating IKr blockers in post-myocardial infarction patients.
- To assess the safety and efficacy of specific IKr blockers for potential use in atrial fibrillation treatment.
Main Methods:
- Review of four clinical trials involving d,l-sotalol, d-sotalol, dofetilide, and azimilide.
- Analysis of drugs with IKr-blocking properties, including beta-blocking (d,l-sotalol) and IKs-blocking (azimilide) effects.
Main Results:
- Results from the reviewed trials were variable, with no significant reduction in mortality observed in post-myocardial infarction patients.
- The primary use for d,l-sotalol, dofetilide, and azimilide is for atrial fibrillation treatment.
Conclusions:
- Mortality trials for these IKr blockers did not demonstrate a reduction in post-infarction deaths.
- These trials are crucial for supporting the regulatory approval of these drugs for atrial fibrillation in high-risk patient populations.
Abstract:
The results of clinical trials in postmyocardial infarction patients using type I antiarrhythmic drugs have been disappointing. There was optimism that IKr blockers might result in a reduction in sudden cardiac death in postinfarct population. Four trials are reviewed here, and the results are variable. The four drugs reviewed--d,l-sotalol, d-sotalol, dofetilide, and azimilide--all share IKr-blocking properties. In addition, d,l-sotalol is a beta-blocker and azimilide is an IKs blocker. The primary uses of d,l-sotalol, dofetilide, and, if approved, azimilide are currently for treatment of atrial fibrillation. Thus, the mortality trials reviewed here are primarily used as support of safety in high-risk patients, because none has achieved a mortality reduction in postinfarction patients. These trials play pivotal roles for regulatory approval of these drugs for use in atrial fibrillation.